Lundbeck in Talks With Possible Alzheimer’s Drug Partners

H. Lundbeck A/S, the Nordic region’s second-largest drugmaker, failed to win recommendation from the European Union’s drug regulator for a treatment for Alzheimer’s disease.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.